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Background: Gastric cancer (GC), an aggressive malignant tumor of the alimentary tract, is a leading cause of
cancer-related death. Circadian rhythm exhibits a 24-hour variation in physiological processes and behavior, such as
hormone levels, metabolism, gene expression, sleep and wakefulness, and appetite. Disruption of circadian rhythm
has been associated with various cancers, including chronic myeloid leukemia, head and neck squamous cell carcinoma,
hepatocellular carcinoma, endometrial carcinoma, and breast cancer. However, the expression of circadian clock genes in
GC remains unexplored.
Methods: In this study, the expression profiles of eight circadian clock genes (PER1, PER2, PER3, CRY1, CRY2, CKIε, CLOCK,
and BMAL1) of cancerous and noncancerous tissues from 29 GC patients were investigated using real-time quantitative
reverse-transcriptase polymerase chain reaction and validated through immunohistochemical analysis.
Results: We found that PER2 was significantly up-regulated in cancer tissues (p < 0.005). Up-regulated CRY1 expression
was significantly correlated with more advanced stages (stage III and IV) (p < 0.05).
Conclusions: Our results suggest deregulated expressions of circadian clock genes exist in GC and circadian rhythm
disturbance may be associated with the development of GC.
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Gastric cancer (GC) is one of the leading causes of
cancer-related death worldwide [1,2]. Early detection of
GC often offers a better prognosis but most patients are
diagnosed with GCs at late stages. Early GC, that is, can-
cer only invading the mucosa or submucosa without
lymph node or distant metastasis, has a >90% 5 year sur-
vival rate regardless of endoscopic or surgical resection.
However, the prognosis of patients with advanced GC is
dismal. Delayed diagnosis at an advanced stage is often
attributable to late onset of clinical symptoms, which
limits available therapeutic approaches in more than
50% of cases [2-4]. Upper gastrointestinal endoscopy is* Correspondence: shlin@cc.kmu.edu.tw; yangmy@mail.cgu.edu.tw
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reproduction in any medium, provided the orthe gold standard for the diagnosis of GC. Endoscopic
ultrasound and abdominal computed tomography are
important tools for preoperative staging. However, pre-
operative staging is sometimes misjudged and correct
cancer staging is confirmed after surgery. Until now, no
useful biomarkers have been available for the prediction
of cancer stage, prognosis or treatment outcome.
The 24-hour rhythmic changes in human physiological
processes and behavior are controlled by autonomous
biological pacemakers, which are called circadian clocks.
The regulation of circadian oscillators occurs through
transcriptional-translational feedback loops, which con-
sist of at least nine core circadian clock genes including
PER1, PER2, PER3, CLOCK, CRY1, CRY2, BMAL1, CK1ε,
and TIM [5-8]. Disruption of circadian rhythms is asso-
ciated with cancer development and tumor progression
[9-11]. Epidemiologic studies of nightshift workers have
revealed that circadian disruption is a critical factor in
the tumorigenesis of breast cancer [12], skin cancer [13],
colorectal cancer (CRC) [14], prostate cancer [15], andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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found that interventions to normalize circadian timing
system dysfunction affect the quality of life and survival
of patients with metastatic colon cancer.
Many recent studies have also demonstrated that the
expression of circadian clock genes is disturbed in cancers
such as hepatocellular carcinoma (HCC) [18], chronic
myeloid leukemia (CML) [19,20], and head and neck squa-
mous cell carcinoma (HNSCC) [21]. However, confirm-
ation of an association between circadian clock genes and
GC is still lacking. Therefore, in this study we studied the
expression of circadian clock genes in GC aiming to find
links between altered circadian rhythm and GC, and assess
the usefulness of these genes as biomarkers to predict dis-
ease severity and treatment outcome.
Methods
Patients and samples
Cancer tissue and the adjacent noncancerous tissues
were obtained from 29 patients (20 men and 9 women)
aged 51–81 years (mean ± standard deviation, 69.76 ±
9.10 years) with gastric adenocarcinoma being treated
with surgery at Changhua Christian Hospital (Changhua,
Taiwan) between 2000 and 2002. Adjacent noncancerous
tissues were obtained 1 cm apart from tumor tissue and
confirmed histologically by a pathologist. Clinical char-
acteristics including patient’s age, sex, tumor staging,
and survival are listed in Table 1. Tumor staging was
used according to the 7th edition of TNM classification
(tumor, lymph node and metastasis) of American Joint
Committee on Cancer which divides GC into stage I, II,
III and IV from early to advanced diseases. The GC tissue
specimens were obtained at the following time points: 21Table 1 Clinical characteristic of the 29 gastric cancer













> 5 years 8
< 5 years 17
Lost to follow-up 4were obtained between 1000 and 1200 hours, and 8 were
obtained between 1200 and 1400 hours. The specimens
were obtained immediately after resection and frozen in li-
quid nitrogen until use. Informed consent was obtained
from all patients after tissue acquisition. This study was
carried out after the approval of the Institutional Review
Board of Changhua Christian Hospital.
Real-time quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) analysis of circadian clock genes
We selected eight circadian clock genes, including PER1,
PER2, PER3, CRY1, CRY2, CKIε, CLOCK, and BMAL1,
to study the expressions in GC. Total RNA was ex-
tracted from cancerous tissue and noncancerous tissue
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
and complimentary DNA was generated with a High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, Foster City, CA, USA) according to the manu-
facturer’s protocols. The designs of the specific forward
and reverse primers and MGB TaqMan® probes and the
reaction conditions for the qRT-PCR of the eight circadian
clock genes were carried out as previously described
[19-21]. Expression of human GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) gene was used for normalizing
circadian clock genes expression in qRT-PCR with an ABI
7700 Sequence Detector (Applied Biosystems). The expres-
sion levels of the circadian clock genes were normalized to
the internal control GAPDH to obtain the relative thresh-
old cycle (ΔCT), and the relative expression between can-
cerous and noncancerous tissues was calculated using the
comparative CT (ΔΔCT) method (ΔΔCT = ΔCT of cancer-




IHC staining was performed on cancerous tissues and
the adjacent noncancerous tissues of GC patients.
Monoclonal or polyclonal antibodies against circadian
clock genes (Abcam Inc. Cambridge, MA, USA) were used
as the primary antibodies. The tissue sections were incu-
bated with primary antibodies (1:200 dilutions) for 1 hour
and then incubated with biotinylated goat anti-rabbit anti-
bodies for 30 minutes. The specific binding of the second-
ary antibodies to the primary antibodies was visualized
using a horseradish peroxidase- diaminobenzidine stain-
ing kit (Abcam Inc.). After staining, the sections were
mounted, cleared, cover-slipped, and examined using a
Zeiss microscope (Zeiss, Gottingen, Germany).
Statistical analysis
Differences in expression between two groups for each
circadian clock gene were detected using a pair t-test,
and the values of ΔCT were used for all the statis-
tical analyses. A Cox proportional hazard regression
model was used for the analysis of circadian clock gene
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lated and a difference was considered statistically sig-
nificant if p value was < 0.05. All computations were
performed using SPSS for Windows Release 13.0 software
(SPSS, Chicago, IL, USA).
Results
Analysis of circadian clock gene expression in GC with
qRT-PCR
Cancerous and noncancerous tissues from 29 patients
with GC were examined for the expressions of the eight
circadian clock genes using qRT-PCR to elucidate whether
the expression levels of circadian clock genes were deregu-
lated in cancer tissues. Our data demonstrated that only
PER2 expression was significantly upregulated (p < 0.005);
differences in expression between cancerous and noncan-
cerous tissues were not statistically significant for the other
seven genes (Figure 1).
Confirmation of circadian clock gene protein expression
using IHC staining
We further investigated the protein expression of the
eight circadian clock genes in GC using IHC staining.
IHC analysis also revealed a higher expression of PER2
proteins in cancerous tissues compared to that in adjacent
noncancerous tissues. An example is shown in Figure 2
and is similar to the results of the other patients. These re-
sults confirmed the qRT-PCR observation that the expres-
sion of PER2 was upregulated in GC tissues. The protein
expression of the other seven circadian clock genes was
not consistently different between cancerous and noncan-
cerous tissues. Some circadian clock proteins could not be
well detected with IHC staining in both cancerous and


































Figure 1 Expression of circadian clock genes in gastric cancer (GC) de
of the eight circadian clock genes in paired cancerous and noncancerous tissu
RNA (mRNA) expression level. The value of mRNA expression in noncancerous
tissues is calibrated to obtain the fold change in cancerous tissues. Statistical sDisease severity and circadian clock gene expression in
GC patients
We divided the patients into earlier stages (stages I and II)
and more advanced stages (stages III and IV) for correl-
ation analysis with circadian clock gene expression and
found that CRY1 expression was upregulated in more ad-
vanced cancer stages (p < 0.05) (Figure 3A). The expression
of the other seven circadian clock genes was not correlated
with GC disease severity.Age and circadian clock gene expression in GC patients
To rule out the possibility that the altered circadian
clock gene expression was due to age differences, we
divided the patients into two groups (< 60 years-old
and > 60 years-old) for correlation analysis with circadian
clock gene expression. The expression of the eight circa-
dian clock genes was not significantly different between
the two groups (Figure 3B).Survival and circadian clock gene expression in
GC patients
The survival status of the patients was followed up for
5 years after surgery. Among the 29 patients, 12 died
from the disease within 2 years, 17 died within 5 years, 8
survived longer than 5 years, and 4 lost to follow up
(Table 1). The correlation between the 2-year or 5-year
survival status and circadian clock gene expression was
further analyzed. None of the eight circadian clock genes
was correlated with either the 2-year or the 5-year sur-
vival (Figure 3C and 3D). However, Cox proportional
hazard regression model analysis has revealed that pa-
tients’ survival days are correlated with the expression
level of PER3 (Odd ratio = 0.901, 95% confidence interval:1 CRY2 CKI CLOCK BMAL1
termined by real-time quantitative RT-PCR. Expression
es from 29 GC patients. The y-axis represents the relative messenger
tissue is designated 1, and the level of mRNA expression in cancerous










CRY2 CLOCK CKI BMAL1
Figure 2 Immunohistochemical analyses of eight circadian clock genes in gastric cancer (GC). A representative case of GC shows higher
expression of PER2 in cancerous tissues compared with that in adjacent noncancerous tissues. Expression of PER1, PER3, CRY1, CRY2, CLOCK, CKIε,
and BMAL1 does not differ between cancerous and noncancerous tissues from GC patients. Original magnification: 400 × .
Hu et al. BMC Gastroenterology 2014, 14:67 Page 4 of 8
http://www.biomedcentral.com/1471-230X/14/670.815-0.997, p = 0.044 ) but not with the other seven circa-
dian clock genes (Table 2).
Discussion
GC is a major health issue and remains a leading cause
of cancer death worldwide. Although early GC has a
good prognosis, most patients are diagnosed at advanced
stages with dismal outcome. To improve the survival in
GC patients, early detection and subsequent surveillance
are essential. Endoscopy with biopsy is the gold standard
in currently available screening and diagnostic tools. Fu-
ture studies should focus on the incorporation of mo-
lecular biomarkers into clinical management to forecast
the cancer stage, prognosis and improve outcome, espe-
cially in advanced-stage GC patients.
Circadian rhythms are endogenously generated rhythms
that occur with a periodicity of approximately 24 hours
and play an important role in regulating the daily rhythms
of human physiology and behaviors. The disruption of
circadian rhythms is considered a contributory factor in
many clinical conditions including sleeping disorders,
gastrointestinal diseases, metabolic syndrome, inflamma-
tion and even cancers [22]. Observational studies have re-
vealed that working a rotating night shift at least three
nights per month for 15 or more years increases the risk
of CRC in women [14]. Night shift work also increasesthe risk of breast cancer [12] and endometrial cancer
[16] in women. Therefore, researchers have considered a
possible link between molecular clock machinery and
some aspects of carcinogenesis such as angiogenesis, cell
proliferation, apoptosis and DNA repair [23]. Indeed, ab-
errant expression of circadian clock genes has been ob-
served in CRC [24], breast cancer [25], and endometrial
cancer [26]; however, associations between the expression
of circadian clock genes and GC have not been reported in
the literature.
In this study, we observed an up-regulation of PER2 in
GCs. PER2 play an important role in tumor suppression
and DNA damage response in vivo [27]. Our previous
studies have revealed down-regulation of PER2 in HCC
[18], CML [19,20], HNSCC [21], and breast cancer [25]
but not in endometrial cancer [26]. Recently, reduced
PER2 expression has also been reported in pancreatic
cancer [28] and CRC [29]. Down-regulated expression of
PER2 has been found in many cancers in both humans
and mice [30,31] and often considered a tumor suppres-
sor gene; however, we cannot explain why upregulated
expression of PER2 has, to date, been found only in GC.
Indeed, the roles of circadian clock genes in the mechan-
ism of carcinogenesis remain to be clarified. The role of
PER2 as a tumor suppressor may not be applicable in all
cancers.
Table 2 Cox proportional hazard regression model analysis
for survival days and circadian clock gene expression in the
29 gastric cancer patients
Relative expression of
circadian clock gene
Hazard ratio 95% CI p value
PER1 1.183 0.971-1.441 0.096
PER2 0.945 0.798-1.120 0.516
PER3 0.901 0.815-0.997 0.044
CRY1 0.879 0.761-1.015 0.079
CRY2 0.926 0.809-1.061 0.268
CKIε 1.024 0.873-1.252 0.819
CLOCK 0.891 0.706-1.124 0.328
BMAL1 0.917 0.802-1.049 0.206
The relative expression of circadian clock genes in cancerous tissue/
































































































Figure 3 Disease severity, age, survival and circadian clock gene expression in gastric cancer (GC) patients. Disease severity (A), age (B),
and survival (C, D) of 29 GC patients were correlated to the expression of eight circadian clock genes. The y-axis represents the relative messenger
RNA expression level. The relative expression in cancerous tissues is calculated by ΔΔCT. The expression in stage I/II (A), age < 60 years
(B) survival > 2 years (C), and survival > 5 years (D) is designated 1 and the relative expression in stage III/IV (A), age > 60 years (B), and survival < 2 years
(C), and survival < 5 years (D) is calibrated to obtain the fold change, respectively. Statistical significance (p < 0.05) was evaluated with a t-test.
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CRY1 in more advanced stage GC but not in earlier
stage. CRY1 is a component of the negative circadian
feedback loop and is essential for the maintenance of
circadian rhythm [32]. CRY1 participates in cell cycle
regulation and the cellular response to DNA damage by
controlling the expression of certain cell cycle genes
[33]. Deregulated CRY1 expression has also been ob-
served in CML [19,20] and HNSCC [21] but not in HCC
[18] or endometrial cancers [26]. A 2013 study by Yu
et al. found up-regulated expression of CRY1 in CRC
cancer tissues compared with that in adjacent noncan-
cerous tissues in 168 CRC patients [34]. Higher CRY1
expression was found in patients with lymph node metas-
tasis and more advanced stages. The authors also found
higher expression of CRY1 correlated positively with poor
patient outcomes. In vitro study, they found overexpressed
CRY1 of CRC cells promote cell proliferation and migra-
tion. In mouse study, nude mice had more obvious tumor
growth after subcutaneously injecting overexpressed CRY1
of human CRC cells compared to that in control group.Their results suggested CRY1 plays an important role in
CRC development and progression both in humans and
mice, and may be a prognostic biomarker in CRC [34].
Similar to these findings in CRC, our study showed CRY1
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cance was not reached for higher CRY1 expression indicat-
ing a poor prognosis, but the results may be limited by the
small number of patients in our study. It is necessary to
collect more cases in the future to validate the relationship
of CRY1 expression and GC cancer stage. CRY1 expres-
sion may be considered a useful biomarker for determin-
ing cancer stage and prognosis in GC patients.
A correction between patients’ survival days and the
expression level of PER3 was also observed in our study.
PER1, PER2 and PER3 genes belong to the same Period
gene family. PER1 and PER2 are important in regulating
the circadian clock [7,9,27] but the exact role of PER3
has not been well described. It has been shown that the
PER1, PER2, PER3 and Dec1 genes are expressed in a
similar circadian manner in human peripheral blood
mononuclear cells, with the peak level occurring during
the habitual time of activity [35] suggesting that the os-
cillation of PER3 may also be an essential factor in
maintaining circadian rhythm. Besides, altered PER3 ex-
pression has been reported in various cancers, includ-
ing CML [19,20], HNSCC [21], HCC [18], and CRC [36].
Further investigations of PER3 function may reveal the
direct links between deregulation of PER3 and prognosis
in GC patients.
Down-regulation of one or more circadian clock genes
has been found in most cancers, which is in contrast to
our findings. Although an aberrant circadian rhythm in
malignant tissues is commonly observed, what is the
exact mechanism through disrupted circadian rhythm to
carcinogenesis remains to be clarified. Gating of the cell
division cycle by the circadian clock has been observed
in some organisms [37,38] and humans. A study by
Bjarnason et al. [39] found correlation with the timing
of circadian clock gene expression in oral mucosa and
the timing of S phase of the cell cycle, suggesting that
the circadian clock may control the timing of cell-cycle
events in tissues. Alteration in the circadian clock genes
expression, regardless up- or down-regulation, breaks the
balance of cell division and results in proliferation of
tumor cells. Disrupted circadian rhythm may therefore
be is both a cause and an effect of cancer.
GC is a multistep and multifactorial disease. Helico-
bacter pylori (Hp) infection is the most important factor
in the pathogenesis of chronic gastritis and is an essen-
tial factor in GC. Hp-related chronic gastritis often re-
sults in atrophic gastritis and intestinal metaplasia which
are indicators of an increased risk of malignant trans-
formation and serve as precancerous markers [40,41].
Gastrointestinal disorders, mainly pain and alterations
in bowel habits, are more common in shift workers
than in day workers. Ulcers have been named the occu-
pational disease of shift workers. Up to date, the asso-
ciation between circadian rhythm disruption and Hp-related gastritis, peptic ulcers or GC has not been well
described. A recent study reported a weak correlation
between shift work and Hp-positive gastritis or upper
gastrointestinal complaints [42] but the results did not
support the conclusion that shift work is related to gastric
disorders. Studies in nocturnal animals have demonstrated
that limiting food availability completely inverts the phase
of the expression of circadian clock genes in peripheral
tissues [43]. During caloric restriction, both the suprachi-
asmatic nucleus (SCN) and peripheral oscillators exhibit
resetting of circadian rhythms [44]. Because circadian
rhythms are directly dictated by food availability, we
hypothesize that circadian rhythm disruption partly in-
volved in the development of GC. Therefore, we first ex-
amined the expression of circadian clock genes in GC and
in hopes of finding a link. Future studies analyzing the
expression of circadian clock genes in Hp-positive and
Hp-negative GCs would be interesting to investigate
the role of Hp in gastric circadian rhythm disturbance.
Whether animal or human, studies have disrupted cir-
cadian rhythms and deregulated expressions of circadian
clock genes in the cancer development and progression.
We hope that the roles of circadian clock genes in the
mechanism of carcinogenesis will be well clarified in
the future.
Conclusions
In this study, we observed an up-regulation of PER2 in
GC, an up-regulation of CRY1 in cancers of more ad-
vanced stage, and a correlation between patients’ survival
days and the expression level of PER3. Our results sug-
gest that deregulated expression of circadian clock genes
exits in GC and that circadian rhythm disturbance may
be associated with the development of GC.
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